Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) Shares Outstanding (Weighted Average) (2024 - 2025)

Caris Life Sciences has reported Shares Outstanding (Weighted Average) over the past 2 years, most recently at $167.2 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $167.2 million for Q4 2025, up 371.04% from a year ago — trailing twelve months through Dec 2025 was $167.2 million (up 371.04% YoY), and the annual figure for FY2025 was $167.2 million, up 371.04%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $167.2 million at Caris Life Sciences, up from $128.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for CAI hit a ceiling of $167.2 million in Q4 2025 and a floor of $35.4 million in Q2 2024.